Affordable Access

Access to the full text

Frontline Maintenance Treatment for Ovarian Cancer

Authors
  • Elyashiv, Osnat1, 2
  • Wong, Yien Ning Sophia1, 2
  • Ledermann, Jonathan A.1, 2
  • 1 University College CRUK and UCL Cancer Trials Centre, London, WC1E 6DD, UK , London (United Kingdom)
  • 2 University College London Hospital, 235 Euston Rd, Fitzrovia, London, NW1 2BU, UK , London (United Kingdom)
Type
Published Article
Journal
Current Oncology Reports
Publisher
Springer-Verlag
Publication Date
Jun 14, 2021
Volume
23
Issue
8
Identifiers
DOI: 10.1007/s11912-021-01088-w
Source
Springer Nature
Keywords
Disciplines
  • Topical Collection on Gynecologic Cancers
License
Green

Abstract

Purpose of ReviewAdvanced epithelial ovarian cancer remains the most lethal gynaecological cancer. Most patients with advanced disease will relapse within 3 years after primary treatment with surgery and chemotherapy. Recurrences become increasing difficult to treat due to the emergence of drug resistance and 5-year survival has changed little over the last decade. Maintenance treatment, here defined as treatment given beyond primary chemotherapy, can both consolidate the response and prolong the control of disease which is an approach to improve survival.Recent FindingsHere we review maintenance strategies such as targeting angiogenesis, interference of DNA repair through inhibition of PARP, combinations of targeting agents, and immunotherapy and hormonal therapy.SummaryMuch has been learnt from the success and challenges of these treatments that have in the last few years which led to significant reduction in disease recurrence, changed the guidelines for treatment, and established a new paradigm for the treatment of ovarian cancer.

Report this publication

Statistics

Seen <100 times